elranatamab will increase the level or impact of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. Elranatamab causes cytokine release syndrome (CRS) that could suppress activity of CYP enzymes, resulting in amplified publicity of CYP substrates.avapritinib and fentanyl transdermal each increase sedat